Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;52(6):76-78.
doi: 10.15586/aei.v52i6.1161. eCollection 2024.

Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics

Diana Betancor  1   2 , Sara Bautista  3 , Raquel López-Rodríguez  4 , Marcela Valverde-Monge  1   2 , Mar Fernández-Nieto  1 , Manuel J Rial  2   3   5
Affiliations

Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics

Diana Betancor et al. Allergol Immunopathol (Madr). .

Abstract

To evaluate the response to Tezepelumab in real clinical practice, we performed an analysis of the clinical, functional, and inflammatory characteristics of 13 patients with severe asthma after completing four doses of Tezepelumab was performed. When comparing clinical parameters such as asthma control test (ACT), FENO value, exacerbations in the last 4 months, blood eosinophils and FEV1%, before receiving Tezepelumab and after four doses of Tezepelumab, statistically significant differences were found in ACT levels (p=0.0072), exacerbations (p=0.018) and FEV1% (p=0.012) before and after four doses of Tezepelumab. No statistically significant differences were found in blood eosinophils or FeNO levels, however, a mean reduction of 102.5±231 cells/mm3 and 14.67±30 ppb, respectively, was observed. Patients with a high T2 profile had significantly higher baseline FeNO (p<0.05), but no significant improvement in lung function or asthma control was observed in this group. Patients with Aspirin-exacerbated respiratory disease (AERD) were evaluated separately. There was no difference in ACT, FeNO, or lung function changes after tezepelumab use compared to patients without AERD (all p>0.05). We demonstrated, in a multicenter study, the clinical improvement associated with tezepelumab treatment in severe uncontrolled asthma, independent of inflammatory biomarkers, eosinophilic profile, or previous biological failure.

Keywords: TSLP; Tezepelumab; biologics; real-world-evidence; severe asthma.

PubMed Disclaimer

References

    1. 1. Ackman H, Jansson S, Stridsman C, et al. Severe asthma–a population study perspective. Clin Exp Allergy. 2019; 49: 819–828. 10.1111/cea.13378 - DOI
    1. 2. Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. 10.3389/fped.2019.00246 - DOI
    1. 3. Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24–37. 10.1016/j.coi.2010.10.020 - DOI
    1. 4. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–9. 10.1056/NEJMoa2034975 - DOI
    1. 5. McDowell PJ, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker S, et al. Exacerbation profile and risk factors in a type-2-low enriched severe asthma cohort: a clinical trial to assess asthma exacerbation phenotypes. Am J Respir Crit Care Med. 2022 Sep 1;206(5):545–553. 10.1164/rccm.202201-0129OC. - DOI

MeSH terms